These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1541 related articles for article (PubMed ID: 15936549)

  • 1. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
    Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
    Kupelian PA; Willoughby TR
    Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma.
    Zelefsky MJ; Leibel SA; Kutcher GJ; Kelson S; Ling CC; Fuks Z
    Cancer J Sci Am; 1995; 1(2):142-50. PubMed ID: 9166467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
    Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
    Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer.
    Aillères N; Azria D; Thézenas S; Barbier N; Fenoglietto P; Delard R; Hay MH; Dubois JB
    Cancer Radiother; 2004 Apr; 8(2):59-69. PubMed ID: 15063872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity.
    Beckendorf V; Guérif S; Le Prisé E; Cosset JM; Lefloch O; Chauvet B; Salem N; Chapet O; Bourdin S; Bachaud JM; Maingon P; Lagrange JL; Malissard L; Simon JM; Pommier P; Hay MH; Dubray B; Luporsi E; Bey P
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1056-65. PubMed ID: 15519775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer.
    Di Muzio N; Fiorino C; Cozzarini C; Alongi F; Broggi S; Mangili P; Guazzoni G; Valdagni R; Calandrino R; Fazio F
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):392-8. PubMed ID: 19056184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of late rectal toxicity from conventional versus three-dimensional conformal radiotherapy for prostate cancer: analysis of clinical and dosimetric factors.
    Lee CM; Lee RJ; Handrahan DL; Sause WT
    Urology; 2005 Jan; 65(1):114-9. PubMed ID: 15667875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.
    Michalski JM; Winter K; Purdy JA; Wilder RB; Perez CA; Roach M; Parliament MB; Pollack A; Markoe AM; Harms W; Sandler HM; Cox JD
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):192-8. PubMed ID: 12694838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy).
    Ryu JK; Winter K; Michalski JM; Purdy JA; Markoe AM; Earle JD; Perez CA; Roach M; Sandler HM; Pollack A; Cox JD
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1036-46. PubMed ID: 12419429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.